ReviewNature reviews. Cardiology2023
Current concepts and novel targets for antiplatelet therapy.
Review in Nature reviews. Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- The NLRP3 inflammasome: a therapeutic target of phytochemicals in treating atherosclerosis (a systematic review).Frontiers in immunology · 2025Pooled it
- Isaridin E Attenuates Ischemic Brain Injury in Mice by Concurrently Reducing Platelet Hyperactivity and Microglial Neuroinflammation Associated with LRP1.Marine drugs · 2026Article
- miR-146a mimic therapy protects against platelet-mediated thrombosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Uniform shear-induced platelet aggregation analysis via microfluidics fabricated from 3D-printed mold: a rapid platform for antiplatelet drug assessment.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2026Article
- Dual Antiplatelet Therapy in Acute Branch Atheromatous Disease (BAD)-Related Stroke: A Multicenter Propensity-Matched Cohort Analysis.CNS neuroscience & therapeutics · 2026Article
- Platelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis.Circulation research · 2026Article
- Panax notoginseng saponins inhibit platelet activation and thrombosis while preserving hemostasis: involvement of platelet oxylipin metabolic reprogramming.BMC complementary medicine and therapies · 2026Article
- Pharmacological Management of Thrombosis: Current State and Future Strategies.International journal of molecular sciences · 2026Review
- Epigenome editing of human hematopoietic stem cells enables sustained and reversible thrombosis prevention.bioRxiv : the preprint server for biology · 2026Article
- Hemostasis-Sparing Antiplatelet Therapy: Current Concepts and Emerging Targets in Arterial Thrombosis.Biomolecules & therapeutics · 2026Review
- Distinct Thromboxane A₂-Dependent Pathways Regulate Arachidonic Acid-Triggered VASP Phosphorylation at Ser239 and Ser157 in Human Platelets: Real-Time Visualization Reveals Superior Antithrombotic Efficacy by Targeting Thromboxane A₂ Signaling over Cyclooxygenase Inhibition.Journal of cellular physiology · 2026Article
- Bannakunin: a dual-target Kunitz inhibitor bridging anticoagulation (FXa/XIIa) and anti-platelet (α2β1/P2Y12) pathways.Cellular & molecular biology letters · 2026Article
- In situ coagulation environment regulation-assisted thrombus clearance via hydrogenated silicon-based nanothrombolytics.Science advances · 2026Article
- Rod-Shaped Nanotherapeutics Alleviate Rheumatoid Arthritis by Precisely Disrupting Platelet-Mediated Pathological Crosstalk via a Morphology-Dependent Manner.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The inhibitory effect of antiplatelet drugs on spontaneous platelet aggregation on glass surfaces: an analysis based on microscopic three-dimensional topography.Journal of thrombosis and thrombolysis · 2026Article
- Qiliqiangxin capsule attenuates platelet activation and thrombosis by suppressing CaThrombosis journal · 2026Article
- Microcirculatory failure after successful recanalization in ischemic stroke: insights into mechanisms, imaging, and therapeutic strategies.Frontiers in pharmacology · 2026Review
- Platelet activation, aspirin, and cancer: From basic science to clinical trials.Pharmacological reviews · 2026Review
- A cecal slurry mouse model of polymicrobial abdominal sepsis to evaluate the effects of antiplatelet agents.Research and practice in thrombosis and haemostasis · 2026Article
- Antiplatelet therapy and central nervous system hematomas: a cohort study using real-world data from the FAERS and VigiAccess databases.International journal of surgery (London, England) · 2026Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelets have a crucial role in haemostasis and atherothrombosis. Pharmacological control of platelet hyper-reactivity has become a cornerstone in the prevention of thrombo-ischaemic complications in atherosclerotic diseases. Current antiplatelet therapies substantially improve clinical outcomes in patients with coronary artery disease, but at the cost of increased risk of bleeding. Beyond their role in thrombosis, platelets are known to regulate inflammatory (thrombo-inflammatory) and microcirculatory pathways. Therefore, controlling platelet hyper-reactivity might have implications for both tissue inflammation (myocardial ischaemia) and vascular inflammation (vulnerable plaque formation) to prevent atherosclerosis. In this Review, we summarize the pathophysiological role of platelets in acute myocardial ischaemia, vascular inflammation and atherosclerotic progression. Furthermore, we highlight current clinical concepts of antiplatelet therapy that have contributed to improving patient care and have facilitated more individualized therapy. Finally, we discuss novel therapeutic targets and compounds for antiplatelet therapy that are currently in preclinical development, some of which have a more favourable safety profile than currently approved drugs with regard to bleeding risk. These novel antiplatelet targets might offer new strategies to treat cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.